Boston Scientific (BSX) Q3 2026 earnings review
Boston Scientific cuts its outlook again as Q3 sales stall
Boston Scientific's growth stalled across both its heart and surgical divisions while production costs took a bite out of margins. Sales of the medical-device maker rose 1.5% to $5.1 billion, missing its 3% to 5% target, and profit per share excluding one-offs fell 3% to $0.73. Chief executive Mike Mahoney pointed to an August cybersecurity incident that disrupted operations, and the company cut its full-year outlook for a third straight quarter.
| Sales from businesses owned a year ago | +1.5% missed the 3%–5% plan |
|---|---|
| Profit per share, excluding one-offs | $0.73 -3% from a year ago (plan: $0.80–$0.82) |
| Gross margin, excluding one-offs | 68.0% -3.0 percentage points from a year ago |
| Full-year underlying sales outlook | Cut to ~3.75% prior plan: 5.0%–6.0% |
⚖️ Verdict: 🔴 Bearish
The story got worse because weakness spread beyond the two heart franchises that drove the prior resets, and the new plan calls for fourth-quarter sales to shrink 1% to 3%. Surgical and urology devices stalled instead of growing at the 6% pace management counted on, while gross margin excluding one-offs dropped 3 percentage points. One bright spot: nerve-stimulation implants grew 13%, and lower overhead plus earlier buybacks cushioned the profit drop.
The question now is how much of the third-quarter miss and fourth-quarter contraction comes from the August cyber outage versus deeper customer losses in heart and urology devices. If the cyber disruption caused most of the gap, sales should rebound early next year; if hospital demand and market share fell further, the slump will last into 2027. The conference call breakdown and the third-quarter filing's product tables will settle it.
🐂 Bull Case
Nerve Devices Grew and Pipeline Clearances Arrived
Boston Scientific relies on new medical devices to rebuild growth by 2028, and its nerve-stimulation unit was the lone bright spot this quarter. Neuromodulation, which makes implants for chronic pain and brain disorders, grew 13.0% on an underlying basis to $331 million, accelerating from 12.2% in the second quarter. While the release did not break out the interventional cardiology unit, the company hit several regulatory milestones across its heart and surgical pipelines.
- Kidney stone care: U.S. clearance for Navigator Flex, a sheath "designed to enable the use of suction to remove kidney stone debris", and the LithoVue Elite scope
- Blocked leg arteries: U.S. clearance for more sizes of the SEISMIQ catheter "to treat patients with severely calcified peripheral artery disease both above and below the knee"
- Stroke prevention: started enrolling patients in the Elite AF trial for the next-generation WATCHMAN Elite heart implant
- Reimbursement: received Category I billing codes, effective January 2028, for the TIVUS high-blood-pressure system and eCoin bladder-control implant
These clearances matter because the urology unit is shrinking and needs the new StoneSmart kidney-stone tools to plug product gaps Management flagged last quarter. Expanding SEISMIQ and partnering with Heartflow on AI-guided heart procedures also advance the cardiology pipeline that underpins the 2028 recovery plan.
What to watch: Interventional Cardiology and Vascular Therapies sales in the third-quarter filing. Double-digit growth there would show the future heart portfolio is holding up even as older products slow.
Lower Overhead and Buybacks Cushioned the Profit Drop
When sales stall, Boston Scientific leans on cost cuts and share buybacks to protect per-share earnings. In July, the medical-device maker approved a restructuring plan to trim $500 million in annual costs by 2029, following a $2 billion share buyback in the second quarter.
Both levers showed up in the third-quarter numbers. Selling, general and administrative expenses (advertising, sales teams and overhead) fell by 1.6 percentage points of revenue from a year ago, to 32.8%. On a basis excluding one-offs, operating expenses dropped 1.5 percentage points to 41.4% of sales. The company also booked $94 million in pre-tax restructuring charges as it ramped up the new cost programme, while the earlier buybacks lowered the diluted share count by 2.9% from a year ago to 1,452 million shares.
What to watch: Selling, general and administrative expenses as a share of sales in the fourth quarter. Another drop during a quarter of shrinking revenue would show the cost programme is delivering early savings.
🐻 Bear Case
Third Outlook Cut Points to Q4 Sales Decline
Three months ago, management cut its full-year plan for a second time and framed the new targets as cautious. Instead, Boston Scientific missed its third-quarter targets and lowered its 2026 outlook for a third consecutive quarter. Chief executive Mike Mahoney said the teams were "working with urgency and resilience to restore operations and continue supporting customers and patients" after an August 26 cybersecurity incident.
- Q3 underlying sales growth: 1.5%, missing the 3.0% to 5.0% plan
- Full-year underlying sales outlook: cut to 3.75%, down from 5.0%–6.0% in July and 10.0%–11.0% in February
- Q4 sales outlook: a drop of 1.0% to 3.0%, vs growth of up to 5.0% implied by the prior plan by our math
- Full-year profit per share outlook, excluding one-offs: cut to $3.16–$3.18 from $3.28–$3.32
The company noted "disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results". Yet a late-August cyber outage does not by itself explain why fourth-quarter sales will shrink 1% to 3% from a year ago, which contradicts the prior framing that the business had found a floor.
What to watch: How much of the shortfall management attributes to the August cyber incident on the conference call and in the quarterly filing. If unshipped orders are not recovered in the fourth quarter, the slowdown is driven by weaker demand rather than a temporary systems outage.
Surgical and Urology Units Stalled Alongside Heart Devices
Last quarter's reset rested on a clear divide: two flagship heart franchises were slowing, while the other three-quarters of the business was supposed to grow about 6% in the second half of the year. In the third quarter, that steady base stalled too.
Cardiovascular sales, which include heart-rhythm and artery devices, grew 1.9% on an underlying basis to $3.41 billion, down from 7.8% growth in the second quarter. Worse for the base-business argument, the MedSurg surgical division slowed from 5.4% underlying growth to 0.7%, generating $1.73 billion. Inside MedSurg, Urology (kidney stone and bladder devices) shrank 3.1% to $661 million, and Endoscopy (digestive and airway scopes) edged down 0.6% to $741 million. Whether caused by the August cyber disruption or softer hospital procedure volumes, the non-heart divisions provided no cushion.
What to watch: Urology and Endoscopy growth in the fourth quarter. A second quarter of contraction in both units would show that weakness has spread beyond the heart portfolio.
Higher Production Costs Cut Gross Margin Three Points
Boston Scientific warned last quarter that slower sales of its highest-profit heart devices would push full-year gross margin below last year's 70.6%. In the third quarter, the margin drop was much sharper than a gradual mix shift, and it dragged operating profit down with it.
Cost of products sold (the direct cost of making and shipping devices) climbed by 3.2 percentage points of revenue from a year ago, to 33.3%. That pushed GAAP gross margin down 3.2 percentage points to 66.7%. Excluding one-offs, gross margin fell 3.0 percentage points from a year ago to 68.0%, and operating margin dropped 1.5 percentage points to 26.5%. Because the company's restructuring plan focuses on administrative overhead first and factory line transfers later, manufacturing savings will not offset this pressure this year.
What to watch: Gross margin excluding one-offs in the fourth quarter. If it stays near 68% after cyber-related shipping disruptions clear, the loss of high-margin heart sales is hurting profitability more than planned.
Risks This Quarter Didn't Answer
The earnings release only provides summary tables, so several standing concerns and watch items await the detailed footnotes in the third-quarter 10-Q filing.
- WATCHMAN heart-implant sales: U.S. sales ($459 million in Q2) and the split between standalone and combined procedures are not in the release; the 10-Q segment note and call remarks will show if standalone procedures kept falling.
- U.S. Electrophysiology sales: U.S. heart-ablation revenue ($606 million in Q2) is not broken out in the release; the 10-Q table will test whether share losses to three rivals worsened.
- Heart rhythm (CRM) and MedSurg margins: segment operating margins and pacemaker sales await the 10-Q segment footnotes.
- Penumbra and MiRus deals: the release gives no update on the $14.5 billion Penumbra acquisition (pending regulator review for a second-half close) or the $1.5 billion MiRus heart-valve option.
- Legal charges: the company booked $81 million in pre-tax litigation charges ($157 million over nine months) without naming the cases; the 10-Q legal note will show how much relates to spinal-cord stimulator lawsuits or the shareholder class action.
💲 Other KPIs
Sales slowed sharply in the United States and Asia while Europe and Latin America held up. U.S. revenue rose 0.5% to $3,309 million, down from 6.2% growth in the second quarter, and Asia-Pacific fell 1.1% excluding currency to $797 million. Europe, the Middle East and Africa grew 6.1% excluding currency to $829 million, and Latin America and Canada rose 10.5%.
Interest expense rose 14.9% from a year ago to $100 million, up from $96 million in the second quarter, reflecting borrowing for the $1.5 billion MiRus investment and the $2 billion share buyback. While the release omits the third-quarter balance sheet, days of inventory on hand had already risen by 26 days from a year earlier to 185 days in the second quarter.
🔮 Guidance
Cut. The medical-device maker lowered its full-year underlying sales growth plan by 1.75 percentage points from the middle of its July range. It is the third straight cut to the 2026 plan, moving the midpoint from 10.5% in February to 7.25% in April, 5.5% in July, and 3.75% today: -3.25 points, -1.75 points, -1.75 points.
Cut. The reported sales growth target dropped 1.75 percentage points from the middle of the prior range, and still includes a 0.5 percentage point boost from foreign currency.
Cut. The middle of the full-year profit per share range, excluding one-offs, dropped 13 cents to $3.17, implying 3.6% growth over 2025 by our math. That marks the third cut this year, with each move larger or similar to the last: -8.5 cents, -7.5 cents, and -13 cents.
Cut. New as an explicit quarterly range, but below the -0.7% to +5.0% growth that the prior full-year plan implied for the fourth quarter by our math. At the -2.0% middle of the range, fourth-quarter sales would be about $5,180 million, up less than 1% from the depressed third quarter.
Cut. The fourth-quarter profit per share target, excluding one-offs, sits below the $0.80 to $0.86 range implied by the prior full-year outlook by our math. The middle of the range ($0.78) is down 2.5% from $0.80 a year ago, ending a streak of double-digit quarterly profit growth in the first half of the year.
❓ Key Questions
How much did the August cyber incident cost in Q3 and Q4?
Sales growth missed the third-quarter plan by 2.5 percentage points and the fourth-quarter outlook calls for a 1% to 3% sales drop. Investors need to know how many millions of dollars in orders were lost to the August 26 cyber outage versus weaker underlying hospital demand.
What were Q3 sales for U.S. WATCHMAN and Electrophysiology?
The earnings release groups all heart businesses into a single Cardiovascular line that grew 1.9%. Without the third-quarter 10-Q breakdown, investors cannot see whether U.S. WATCHMAN ($459 million in Q2) and U.S. Electrophysiology ($606 million in Q2) fell in line with management's prior forecast.
Why are free cash flow and tax targets missing from the release?
Last quarter, management guided full-year free cash flow to about $3.8 billion, operating cash flow to $4.7 billion, and the adjusted tax rate to 11.5%. With full-year earnings cut by 13 cents per share, management needs to state where cash generation now stands.
What drove the $81 million litigation charge this quarter?
Boston Scientific booked $81 million in pre-tax litigation charges in the third quarter, bringing the nine-month total to $157 million. Management has not yet said how much of that relates to the consolidated spinal-cord stimulator lawsuits or the shareholder class action.